Key facts
- It has raised $27.8M; the latest was Early Stage VC ($13.9M) in Aug 2025.
- Notable investors include Jolmo Investment, Huatai Zijin Investment, Jinding Capital, Xiaofanzhuo, Fan Zhuo Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Xiushi Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Xiushi Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xiushi Biotech
Developer of peptide drug biosynthesis technology intended for global biotechnology firms, pharmaceutical companies, and contract development and manufacturing clients. The company is engaged in the peptide drug development and manufacturing platform, featuring large-scale biosynthesis capabilities, GMP-compliant facilities, and advanced CMC development processes, thereby enabling clients to accelerate drug discovery, reduce production costs, and achieve sustainable manufacturing.
- Sector
- Healthcare
- HQ
- Nantong, China
- Founded
- 2020
- Website
- xiushi-bio.com/
- Ownership
- Privately Held (backing)
Xiushi Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xiushi Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xiushi Biotech in its N-PORT filings yet. We sweep new filings monthly.